Navigation Links
Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Date:10/8/2009

SEATTLE, Wash., Oct. 7 /PRNewswire-FirstCall/ -- Omeros Corporation today announced the pricing of its initial public offering of 6.82 million shares of its common stock at a price of $10.00 per share. The underwriters have the option to purchase up to an additional 1.02 million shares to cover over-allotments, if any. All of the shares of common stock are being offered by Omeros. The common stock is expected to begin trading on The NASDAQ Global Market on October 8, 2009 under the ticker symbol "OMER."

Omeros intends to use the net proceeds of the offering to fund the completion of its Phase 3 clinical trials of OMS103HP, its lead product candidate being evaluated for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain, as well as the potential launch and commercialization of OMS103HP. The Company also intends to use the net proceeds to fund, among other things, the development of its other product candidates in the clinic, OMS302 for ophthalmology and OMS201 for urology, and the development of its pipeline of preclinical programs.

Deutsche Bank Securities Inc. is acting as the sole book-running manager. Wedbush PacGrow Life Sciences is acting as the co-lead manager, Canaccord Adams and Needham & Company, LLC are acting as co-managers, and Chicago Investment Group, LLC and National Securities Corporation are acting as junior co-managers.

The offering will be made only by means of a prospectus, copies of which may be obtained by contacting: Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 7, 2009. This press release shall not constitute
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
7. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
8. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
(Date:1/22/2015)... Corporation (NASDAQ: TECH ) announced today that ... new Simple Plex platform through its Proteins Platform division ... of the previously acquired CyPlex instrument platform from CyVek. ... immunoassay technology which integrates an innovatively designed microfluidic cartridge ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... , FRIDAY, Sept. 9 (HealthDay News) -- Good hygiene ... bacterial and viral infections, according to the U.S. Centers ... growing concern that strict adherence to good hygiene, though ... open to other forms of illness. Proponents of ...
... -- More than one-half of all adverse drug reactions ... to a new study. In addition, prior research ... include drug overdoses and internal bleeding associated with the ... life-threatening, said the Swedish researchers. This widespread problem, which ...
... News) -- Having control over how to communicate with ... patients cope with their situation, according to a new ... Austin interviewed cancer survivors about strategies they used in ... about their condition, challenges they faced, advice they received, ...
... finds that lung cancer patients treated in hospitals ... and Medicaid-insured patients, so-called "high safety-net burden facilities," ... was intended to cure the cancer compared to ... difference persisted even after controlling for other factors ...
... Reinberg HealthDay Reporter , FRIDAY, Sept. 9 ... and Drug Administration were to meet Friday to discuss ... as Fosamax, Actonel, Boniva and Reclast. These ... related to postmenopausal osteoporosis. But researchers have linked long-term ...
... vaccine Cervarix may be just as effective as the standard ... cancer, according to a new study published September 9 in ... Across the globe, cervical cancer is the third most ... are a large contributor to the development of the disease. ...
Cached Medicine News:Health News:A Little Dirt May Be a Good Thing 2Health News:A Little Dirt May Be a Good Thing 3Health News:Over Half of Adverse Drug Reactions in Hospitals Are Preventable: Study 2Health News:Talking -- or Not Talking -- Can Give Cancer Patients a Sense of Control 2Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:Fewer than 3 doses of cervical cancer vaccine effective 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: